2024
BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Hsu F, Lumry W, Aygoren-Pursun E, Braverman J, Lawo J, Pollen M, Nenci C, Craig T. BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s33-s34. DOI: 10.1016/j.anai.2024.08.129.Peer-Reviewed Original ResearchOpen-label extensionAttack-free patientsHereditary angioedemaHRQoL improvementAttack-freeImpaired health-related quality of lifeHealth-related quality of lifeAE-QoLClinically meaningful HRQoL improvementAssociated with HRQoL improvementsExposure cohortPhase 3 studySustained HRQoL improvementQuality of lifePost hoc analysisHRQoL outcomesScore reductionHRQoLPatientsHoc analysisCohortTreatment goalsImpairment scoresAngioedemaDisease control
2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy, Asthma & Clinical Immunology 2020, 16: 8. PMID: 32042283, PMCID: PMC7001333, DOI: 10.1186/s13223-020-0409-3.Peer-Reviewed Original ResearchOpen-label extensionC1-INHHealthy babyFemale subjectsFirst trimesterSubgroup analysisHereditary angioedemaHAE-C1INHIU/Severe angioedema attacksSubcutaneous C1-INHPhase 3 trialParallel-arm trialAttacks/monthLong-term efficacyFemale sex hormonesPre-study periodSubgroup of subjectsHAE attacksRoutine prophylaxisEfficacy endpointEligible subjectsUneventful pregnancyAngioedema attacksSex hormones